TB/ HIV CONTROL AND MANAGEMENT IN SOUTH AFRICA

Slides:



Advertisements
Similar presentations
TB/HIV Integration What it entails Frank Lule, Eyerusalem Negussie, Reuben Granich, Haileyesus Getahun.
Advertisements

Exploring Synergies Health Systems and Sustainability TB/HIV collaboration Alasdair Reid UNAIDS Pretoria International Multistakeholder Consultation on.
Improving diagnosis TB laboratory strengthening.
Involving all health care providers in collaborative TB/HIV activities Eva Nathanson PPM subgroup meeting Cairo, Egypt, 3-5 June 2008.
Of South Africa DOTS WORKS VWSA WORKPLACE PROGRAM.
TB and poverty agenda in WPR WHO/WPRO Stop TB. World Health Organization Percentage of population living below US$1 a day.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
Dr R.Reesaul Chest Physician Chest Clinic P. D`or Hospital
Monitoring and Evaluation Frameworks Kyiv, Ukraine May 23, 2006 MEASURE Evaluation.
Monitoring and Evaluation: Tuberculosis Control Programs
Introduction Hypothesis Conclusions Specific Aims In-home Intervention Improves Outcomes of Tuberculosis Patients in Zimbabwe, Africa Olga Kishek, Tess.
Monitoring and Evaluation Frameworks   What is an M&E Framework?   Why do we use M&E Frameworks?   How do we develop M&E Frameworks? MEASURE Evaluation.
National TB/ Leprosy Programme Manager
experience from Lesotho
Molecular methods for TB drug resistance testing: what is needed? Experience from Khayelitsha, Cape Town, South Africa Helen Cox, PhD, Burnet Institute.
Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.
MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.
Challenge 4: Linking TB & HIV/AIDS Programs Kayt Erdahl, Project HOPE Rodrick Nalikungwi, Project HOPE Malawi December 18, 2008.
NATION-WIDE SCALE UP OF TB/HIV COLLABORATIVE ACTIVITIES: Secrets of South Africa! Lerole David Mametja International AIDS Conference 24 July 2012 Washington.
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
IMPLEMENTATION PLAN TO SCALE UP HIV/AIDS PREVENTION AND TREATMENT 1.
A decentralized model of care for drug-resistant tuberculosis in a high HIV prevalence setting Cheryl McDermid, Helen Cox, Simiso Sokhela, Gilles van Cutsem,
 To what extent is IMCI implemented in NWP and what are the obstacles to its implementation?  What is the impact of IMCI in NWP?  What is the impact.
Max O’Donnell, Nesri Padayatchi, Iqubal Master, Garth Osburn, Robert Horsburgh Treatment of Extensively Drug Resistant Tuberculosis Among Patients with.
6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,
African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.
Missed opportunities to diagnose TB and HIV Co-infection in HIV workplace program Dr Fred Mugyenyi Asiimwe Medical Director, ALAFA.
Universal access to TB care what is the challenge, what policy, what is being implemented Cancun 3 December 2009 Léopold BLANC and TBS team TBS/STB/WHO.
NATIONAL TB 2012 INDICATOR ANALYSIS REPORT Presented by: Sandile Ginindza Lugogo Sun Hotel 05 th -7 th June 2013 Ministry of Health NTCP.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
TB, MDR-TB and XDR-TB in South Africa October 2006.
Integrating TB in the Workplace Presentation by: Miss. D.M.Nokwe 15 th of October 2009 TB Directorate.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
Improving the tuberculosis control using the Directly Observed Treatment programme in Limpopo Province, South Africa 4 th International Conference on Nursing.
H Bygrave L Triviño L Makakole Medecins sans Frontieres Lesotho Scott Hospital Morija TB/HIV Integration Lessons learned from implementation of a TB/HIV.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
Fiorenza Monticelli Gauteng District Health Systems Summit 22 August 2008.
Global Tuberculosis Control 2007 Did we reach the 2005 targets? Will we achieve the Millennium Development Goals?
Gap Analysis: Tuberculosis Care in Malawi Round 11 proposal to the Global Fund to Fight AIDS, Tuberculosis and Malaria Africa 3: Team Malawi Arianna, Babatunde,
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
TB infection control in the era of MDR and XDR TB Haileyesus Getahun Stop TB Department WHO/HQ.
Taipei, June Content  Introduction about Vietnam’s Programmatic Management of Drug resistant Tuberculosis (PMDT) and drug resistant tuberculosis.
TB-HIV Last updated: January 2017.
Monitoring and Evaluation Frameworks
Addressing the challenges and successes of expediting TB treatment among PLHIV who are seriously ill: experience from Kenya Masini E & Olwande C National.
Prisons and TB in Europe
Free State TB Information
Nazir Ismail CTB/NICD & WHO-SRL & UP
Progress in Implementing collaborative TB/HIV activities
TB-HIV Last updated: March 2018.
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
TB-HIV Last updated: November 2018.
Models of Care for People with Drug-Resistant TB: Advancements in South Africa Dr. Norbert Ndjeka MD, DHSM (Wits), Dip HIV Man (SA), MMed (Fam Med) (MED)
Key issues in DOTS implementation
Indian Scenario HIV Situation TB Situation
From TB control to integrated respiratory disease control
DOTS IMPACT TO TUBERCULOSIS IN LITHUANIA
Cheng shiming National TB Center in China May,3, 2004
National Tuberculosis Control Program in Vietnam
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
EXERCISE 11: Computing and Analyzing Program Indicators
South Africa: From ProTest to Nationwide Implementation
From ProTEST to Nationwide Implementation
Issues on the current information system
The STOP TB Strategy – 2009 VISION: A TB-free world
LESSONS FROM IMPLEMENTATION Dr Kgomotso Vilakazi Nhlapo
Surveillance, Monitoring and Evaluation Working Group
Routine Counselling and HIV testing (CT) for TB patients in Malawi: Rhehab Chimzizi TB-HIV Programme officer National TB Control Programme-Malawi.
Presentation transcript:

TB/ HIV CONTROL AND MANAGEMENT IN SOUTH AFRICA Prelimanary Report on TB Data 2004 CF & 2003 TO TB/ HIV CONTROL AND MANAGEMENT IN SOUTH AFRICA Lindiwe Mvusi Prepared by Carina Idema

Estimated Global TB Burden: 2009

Estimated incidence of new TB cases: 2009

Global MDR-TB Burden: 2009

HIV Prevalence among new TB cases: 2009

10 Leading underlying natural causes of death STATSSA, Mortality and causes of death in South Africa, 2008 Findings from death notification, 2010

Trends in TB Notifications: 2000 - 9

TB Case Notifications – 2008/9

Why is case detection low? TB in children missed Screening and diagnosis in HIV positive people low Contact screening not conducted Delays in diagnosis due to Low index of suspicion by HCW Lack of awareness by communities Poor access to services – facilities/ labs

HIV PREVALENCE 2009, BY DISTRICT

Prelimanary Report on TB Data 2004 CF & 2003 TO TB and HIV Indicators 2005 2006 2007 2008 2009 TB patients tested 76988 110235 136247 150542 197448 TB patients HIV pos 35299 58249 87764 89950 114523 Co-infected started on CPT 57053 58801 64348 80954 Co-infected started on ART 11654 23344 20689 22107 48314 Total number HIV positive 458618 379672 668414 844617 HIV pos screened for TB 103056 150092 364261 433662 HIV pos diagnosed with TB 30026 15521 27391 54406 HIV pos started on IPT 2512 5642 15355 23583 Prepared by Carina Idema Prepared by Carina Idema 11

Treatment outcomes, 2000-08 Year Cure rate (%) Treatment success (%) Death rate (%) Failure rate (%) Defaulter rate (%) Transfer rate (%) Not evaluated (%) 2008 67.0 76 8.0 1.8 7.5 4.8 1.9 2007 62.5 71.7 7.4 8.2 5.1 5.9 2006 62.9 73.8 7.3 1.7 9.1 5.2 2.9 2005 57.6 70.8 10.4 5.5 4.3 2004 50.8 65.5 7.1 1.5 10.3 5.8 9.9 2003 50.9 1.2 11.2 7.0 10.2 2002 50.0 63.0 11.9 9.0 2001 49.7 60.5 6.7 11.1 12.7 2000 53.8 6.5 1.3 13.5 -

Reasons for the poor treatment outcomes Poor support systems in communities Access to health facilities Health care worker attitudes Substance/ alcohol abuse Migration Poor patient knowledge and understanding Stigma – family, community, work, clinic Poor referrals and follow up systems

Estimated burden of MDR-TB:2001 Worst case scenario Best case scenario EC 2142 1169 FS 305 212 GP 1213 660 KZN 2616 1385 LP 832 455 MP 906 484 NC - NW 592 322 WC 770 422 Total 9329 4983

Prevalence of resistance among retreatment cases MDR-TB (%) Retreatment after cure 3.4 Retreatment after failure 25.5 Retreatment after default 7.4 Retreatment after completion 6.8 Unknown/ Other 7.2 Total 6.6

TB Drug Resistance, 2001 by province NEW RETREATMENT MDR-TB Any H Any R New Retreatment EC 7.1 1.2 13.4 7.8 1.0 7.4 FS 6.4 2.4 6.9 2.9 1.8 1.7 GP 4.4 9.7 6.1 1.4 5.5 KZN 5.4 14.5 8.7 7.7 LP 12.5 10.2 6.8 MP 7.0 3.1 18.9 16.0 2.6 13.7 NC - NW 5.9 2.7 11.2 9.6 2.2 WC 5.2 0.9 6.6 3.9 Total 5.7 11.8 7.5 1.6

MDR-TB Notifications 2004-9 2005 2006 2007 2008 2009 EC 379 545 836 1092 1501 1858 FS 116 151 198 179 381 253 GP 537 676 732 986 1028 1307 KZN 583 1024 2200 2208 1573 1773 LP 59 40 77 91 85 204 MP 162 134 139 506 657 446 NC 168 155 188 199 290 631 NW 130 203 225 397 363 520 WC 1085 1192 1179 1771 2220 2078 SA 3219 4120 5774 7429 8198 9070

XDR-TB Notifications 2004-9 2005 2006 2007 2008 2009 EC 3 18 61 108 175 123 FS 1 6 4 GP 5 14 19 38 30 65 KZN 59 227 336 241 181 254 LP - 2 MP 12 NC 10 7 40 NW 9 13 WC 16 28 42 60 72 SA 85 298 464 458 488 594

Prelimanary Report on TB Data 2004 CF & 2003 TO Conclusion Good quality data, regular supervision and programme reviews as well as ongoing operational research are key to assessing programme performance and impact of interventions that are implemented. Prepared by Carina Idema Prepared by Carina Idema 19

Prelimanary Report on TB Data 2004 CF & 2003 TO Thank you for listening “STOP TB …….. BECAUSE YOU CAN” Prepared by Carina Idema